Novartis’ Phase 3 cholesterol study fails key cardiovascular goal
Novartis said a highly anticipated cholesterol drug failed in a Phase 3 study to reduce the risk of severe cardiovascular outcomes, according to reporting by WSJ.
By Lizzy Lawrence and Xavier MartinezA highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study, dealing a blow to the company and others exploring a new approach to prevent cardiovascular disease.The company said that the drug…